[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@ViatrisInc Avatar @ViatrisInc Viatris

Viatris posts on X about madrid, $vtrs, premiere, fda the most. They currently have XXXXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

Mentions: X #

Mentions Line Chart

Followers: XXXXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence #

Social category influence travel destinations stocks finance countries

Social topic influence madrid, $vtrs, premiere, fda, japan, acquisition, people with

Top assets mentioned Viatris Inc (VTRS)

Top Social Posts #

Top posts by engagements in the last XX hours

"Today we announced positive top-line results from our second pivotal Phase X VEGA-3 Trial in presbyopia. Read for more information here:"
X Link @ViatrisInc 2025-06-26T11:02Z 8507 followers, XXX engagements

"We are celebrating a big win by #TeamCongress at last weeks @CWSoftballGame In addition to bringing together bipartisan lawmakers and members of the press corps this game supports @YSCBuzz in its mission to address the unique needs of young adults affected by breast cancer"
X Link @ViatrisInc 2025-07-22T19:13Z 8510 followers, XXX engagements

"Visit booth A200 at the #ESCCongress in Madrid to watch the premiere of a film we created with @BBCStoryWorks dedicated to raising awareness on the importance of early detection of heart attack symptoms. Look for the full video later this month. #ESCCongress #WCCardio"
X Link @ViatrisInc 2025-08-30T11:48Z 8507 followers, XXX engagements

"Yesterday we announced positive top-line results from two pivotal Phase X studies of MR-107A-02 for the treatment of moderate-to-severe acute pain. Read for more information here:"
X Link @ViatrisInc 2025-05-09T11:00Z 8510 followers, XXX engagements

"Today we announced top-line results from our Phase X LYNX-2 Trial in keratorefractive patients with visual disturbances under mesopic low-contrast conditions. Read for more information here:"
X Link @ViatrisInc 2025-06-02T12:04Z 8510 followers, XXX engagements

"$VTRS reports second quarter 2025 results and reiterates 2025 financial guidance. Read our press release for more information including non-GAAP financial measure reconciliations and risks related to fwd-looking statements"
X Link @ViatrisInc 2025-08-07T11:12Z 8510 followers, XXX engagements

"Today we announced the FDA approval of the first generic iron replacement product to treat iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD)helping facilitate increased access to this complex injectable product. Information here:"
X Link @ViatrisInc 2025-08-11T13:34Z 8507 followers, XXX engagements

"We recently announced positive results from Phase X study of investigational XULANE LO low dose patch for birth control in women of childbearing potential. Read for more information here:"
X Link @ViatrisInc 2025-05-12T11:15Z 8508 followers, XXX engagements

"$VTRS completes acquisition of Aculys Pharma including exclusive rights to pitolisant in Japan and to Spydia in Japan and certain other markets in the Asia-Pacific region. Read more:"
X Link @ViatrisInc 2025-10-15T20:34Z 8506 followers, XXX engagements

"This week we join global experts at #APLAR2025 to advance care for people with systemic lupus erythematosus (SLE) where our team will present insights from the Phase X CARE studyunderscoring our commitment to addressing unmet medical need in SLE"
X Link @ViatrisInc 2025-09-04T17:26Z 8507 followers, XXX engagements

"Our team is on site at #PAINWeek2025 stop by to learn more about our efforts in addressing acute and chronic pain and our Phase X program evaluating our investigational asset in moderate-to-severe acute surgical pain models. Read to learn more:"
X Link @ViatrisInc 2025-08-31T11:01Z 8507 followers, XXX engagements

"We are here in Madrid at the #ESCCongress. Visit us at booth A200 to learn more about our efforts in reducing the burden of cardiovascular diseases and the latest on the SOS-AMI trial. #ESCCongress #WCCardio"
X Link @ViatrisInc 2025-08-27T13:02Z 8510 followers, XXX engagements

"Today we provided an update on the Phase X Study of MR-139 for Blepharitis. Read more information here:"
X Link @ViatrisInc 2025-07-18T11:04Z 8510 followers, XXX engagements

"At the #AAOpt Congress results from our Phase X LYNX-2 trial were presented highlighting our investigational asset being evaluated in keratorefractive patients with visual disturbances under mesopic low-contrast conditions. Read more:"
X Link @ViatrisInc 2025-10-15T12:01Z 8506 followers, XXX engagements

"At #PAINWeek2025 we presented X abstracts from our Phase X program evaluating our investigational asset in moderate-to-severe acute surgical pain models which further highlighted positive results from two previously announced Phase X studies. Learn more:"
X Link @ViatrisInc 2025-09-06T10:01Z 8507 followers, XXX engagements

"We have been named to Forbes list of the Worlds Best Employers for the 5th year in a row Learn more about our culture that prioritizes wellbeing promotes inclusivity offers training learning and development opportunities and enables high performance"
X Link @ViatrisInc 2025-10-08T15:06Z 8506 followers, XXX engagements

"Today we announced that five abstracts from our Phase X program evaluating novel fast-acting formulation of meloxicam (MR-107A-02) in moderate-to-severe acute surgical pain models will be presented at the PAINWeek 2025 national conference. Learn more:"
X Link @ViatrisInc 2025-08-01T14:07Z 8510 followers, XXX engagements